Fmr LLC Trims Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Fmr LLC cut its holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 7.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 71,164 shares of the biopharmaceutical company’s stock after selling 5,917 shares during the period. Fmr LLC’s holdings in Esperion Therapeutics were worth $117,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ESPR. Intech Investment Management LLC purchased a new stake in Esperion Therapeutics during the third quarter worth approximately $94,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Esperion Therapeutics by 71.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company’s stock valued at $1,174,000 after purchasing an additional 295,378 shares during the last quarter. Summit Wealth Group LLC bought a new stake in shares of Esperion Therapeutics in the third quarter worth $66,000. Versor Investments LP bought a new stake in Esperion Therapeutics in the third quarter valued at about $44,000. Finally, Traphagen Investment Advisors LLC acquired a new stake in shares of Esperion Therapeutics during the 3rd quarter valued at approximately $27,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Stock Performance

ESPR opened at $2.19 on Monday. The firm has a market cap of $431.51 million, a P/E ratio of -3.42 and a beta of 1.01. Esperion Therapeutics, Inc. has a twelve month low of $1.58 and a twelve month high of $3.94. The business has a 50 day moving average price of $2.42 and a 200 day moving average price of $2.22.

Wall Street Analyst Weigh In

ESPR has been the topic of a number of research reports. The Goldman Sachs Group initiated coverage on Esperion Therapeutics in a research report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research report on Thursday, December 12th. Cantor Fitzgerald initiated coverage on Esperion Therapeutics in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Esperion Therapeutics in a research note on Friday, December 13th. Finally, StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $7.30.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.